Tag Archives: Ram Selvaraju

H.C. Wainwright Maintains a Buy Rating on Chromadex (CDXC)

H.C. Wainwright analyst Ram Selvaraju maintained a Buy rating on Chromadex (CDXC – Research Report) today and set a price target of $11.00. The company’s shares closed last Friday at $7.53. According to TipRanks.com, Selvaraju is a 3-star analyst with

H.C. Wainwright Thinks Provention Bio’s Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Provention Bio (PRVB – Research Report) today and set a price target of $27.00. The company’s shares closed last Tuesday at $7.73, close to its 52-week low of $6.36. According

Urogen Pharma (URGN) Receives a Buy from H.C. Wainwright

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Urogen Pharma (URGN – Research Report) today and set a price target of $50.00. The company’s shares closed last Monday at $20.85. According to TipRanks.com, Selvaraju is a 5-star analyst

Inovio Pharmaceuticals (INO) Receives a Hold from H.C. Wainwright

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research Report). The company’s shares closed last Friday at $6.85, close to its 52-week low of $6.49. According to TipRanks.com, Selvaraju

H.C. Wainwright Reaffirms Their Buy Rating on NeuroBo Pharmaceuticals (NRBO)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on NeuroBo Pharmaceuticals (NRBO – Research Report), with a price target of $16.00. The company’s shares closed last Monday at $3.12, close to its 52-week low

H.C. Wainwright Sticks to Its Hold Rating for Inovio Pharmaceuticals (INO)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Inovio Pharmaceuticals (INO – Research Report). The company’s shares closed last Thursday at $9.01, close to its 52-week low of $6.88. According to TipRanks.com, Selvaraju